BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7949092)

  • 1. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
    van Genderen PJ; Vink T; Michiels JJ; van 't Veer MB; Sixma JJ; van Vliet HH
    Blood; 1994 Nov; 84(10):3378-84. PubMed ID: 7949092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor.
    Mohri H; Hisanaga S; Mishima A; Fujimoto S; Uezono S; Okubo T
    Blood Coagul Fibrinolysis; 1998 Jan; 9(1):91-7. PubMed ID: 9607124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
    Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein ib. Recognition site is located in the A1 loop of von Willebrand factor.
    Mohri H; Yamazaki E; Suzuki Z; Takano T; Yokota S; Okubo T
    Thromb Haemost; 1997 Apr; 77(4):760-6. PubMed ID: 9134656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
    Fricke WA; Brinkhous KM; Garris JB; Roberts HR
    Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor.
    Mohri H; Tanabe J; Ohtsuka M; Yoshida M; Motomura S; Nishida S; Fujimura Y; Okubo T
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):561-6. PubMed ID: 7578899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
    Dicke C; Schneppenheim S; Holstein K; Spath B; Bokemeyer C; Dittmer R; Budde U; Langer F
    Ann Hematol; 2016 May; 95(6):945-57. PubMed ID: 27040683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
    Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.
    Favaloro EJ; Dean M; Grispo L; Exner T; Koutts J
    Am J Hematol; 1994 Mar; 45(3):205-11. PubMed ID: 8296790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.
    Casonato A; Pontara E; Doria A; Bertomoro A; Cattini MG; Gambari PF; Girolami A
    Br J Haematol; 2002 Mar; 116(4):899-904. PubMed ID: 11886398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
    Favaloro EJ
    Semin Thromb Hemost; 2002 Apr; 28(2):191-202. PubMed ID: 11992242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
    Mohri H
    J Thromb Thrombolysis; 2003 Jun; 15(3):141-9. PubMed ID: 14739623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.